The investigational radioisotope, F-18 FLT (fluorothymidine), is showing promise in clinical trials in the ability to assess response to cancer treatment. Research into the clinical applications of the FLT radiotracer has been underway for over 10 years. After FDA approval for use in clinical trials, the molecular imaging community is holding much promise in the